Cardiovascular Systems Completes Enrollment Of ECLIPSE Clinical Trial
$CSII
Medical/Dental Instruments
Health Care
Cardiovascular Systems Completes Enrollment Of ECLIPSE Clinical Trial
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $15.00 | Equal Weight | Barclays |
| 12/14/2022 | $25.00 | Buy | Lake Street |
| 3/2/2022 | $22.00 | Underperform | BofA Securities |
| 2/4/2022 | $25.00 → $20.00 | Outperform | SVB Leerink |
| 11/17/2021 | Buy → Hold | Needham | |
| 11/10/2021 | Buy → Neutral | Guggenheim | |
| 11/10/2021 | $45.00 → $40.00 | Outperform | SVB Leerink |
| 9/23/2021 | $50.00 → $49.00 | Buy | Needham |
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin
Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla
Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor
Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $15.00
Lake Street initiated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $25.00
BofA Securities resumed coverage of Cardiovascular Systems with a rating of Underperform and set a new price target of $22.00
MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
-S&P Global
The Office of Senator Tina Smith has reported a sale of Cardiovascular Systems (NASDAQ:CSII) stock on April 19, 2023. According to the April filing, the transaction was made on April 19, 2023. What Happened: A recent report from the U.S. Senate's Office on April 19, 2023 reveals that Smith made a sale of Cardiovascular Systems stock valued between $100,002 - $200,000. Cardiovascular Systems shares are trading down 0.0% at $19.97 at the time of writing. The Importance of Congressional Transactions Congressional transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider. A Congressional transaction is when any Re
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C
Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin
15-12G - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)